Back to search

Article

Measuring the Impact of Global R&D Investment in Product Development Partnerships (PDPs): A Case Study on Return on Investment in Antimalarial Drug Development

2025-06-17

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Product Development Partnerships (PDPs) are non-profit organizations that bridge the gap between the need for new treatments for poverty-related diseases and the resources available to develop them, leveraging a mix of public, philanthropic, multilateral, and private sector funding. This paper describes how two financial metrics were used to estimate the return on investment...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4e11c8bb-1ae2-5539-a5bf-fc9eb4c063cc
DOI
10.1101/2025.06.17.25329737
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Measuring the Impact of Global R&D Investment in Product Development Partnerships (PDPs): A Case Study on Return on Investment in Antimalarial Drug DevelopmentDOI 10.1101/2025.06.17.25329737
The Allocation of US$ 105 Billion in Global Funding for Infectious Disease Research between 2000 and 2017: An Analysis of Investments from Funders in the G20 CountriesSemantic proximity
Financial Feasibility Study and policy recommendations of Incremental Modified Drugs Development by the Domestic Pharmaceutical IndustrySemantic proximity
Social and private value created through commercialization of Gilead Sciences’ innovative medicines for Hepatitis C and HIV: a cross-sectional analysisSemantic proximity
Preparing for Next-Generation Antimalarials in Nigeria: A Pre-Introduction Readiness Assessment with Focus on Infant-Friendly Formulations and Emerging TherapiesSemantic proximity
The 10-year health impact, economic impact, and return on investment of the South African molecular diagnostics programme for HIV, Tuberculosis and SARS-CoV-2Semantic proximity
Developing an Aggregator Mechanism for Late-Stage Clinical Trials of Neglected Disease Product CandidatesSemantic proximity
Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?Semantic proximity
Assessing the Value of Integrated Evidence Approaches in Drug DevelopmentSemantic proximity
The Net Financial Benefits of Single Vendor Integrated CDMO and CRO Drug Development ServicesSemantic proximity
Evolving priorities in malaria research in Indonesia (2015–2025): A scoping review and bibliometric analysisSemantic proximity
Estimating the Risk of Declining Funding for Malaria in Ghana: The case for continued investment in the malaria responseSemantic proximity
Financing translation: Analysis of the NCATS rare-diseases portfolioSemantic proximity
Select a neighboring publication to make it the new centre.